In Vivo CAR T: A New Route to Treating Autoimmune Disease
How targeted in vivo CAR T delivery could pave the way for autoimmune disease treatments
By
Ying K. Tam
Sean Semple
July 13, 2026
Clinical Scorecard: In Vivo CAR T: A New Route to Treating Autoimmune Disease
At a Glance
Category Detail
Condition Autoimmune Diseases Key Mechanisms In vivo generation of CAR T-cells targeting B-cells to reset the immune system. Target Population Patients with autoimmune conditions such as lupus and multiple sclerosis. Care Setting Clinical research and specialized medical centers.
Key Highlights
In vivo CAR T-cell therapy shows promise for treating autoimmune diseases. Technological advancements enable targeted delivery of CAR T-cells. Modified lipid nanoparticles (LNP) improve specificity and reduce liver uptake. DARPins offer a smaller, more effective targeting alternative to antibodies. Potential for long-term remission in autoimmune patients with high unmet needs. Guideline-Based Recommendations
Diagnosis
Identify autoimmune conditions with high B-cell involvement. Management
Consider in vivo CAR T-cell therapy for eligible patients. Monitoring & Follow-up
Assess safety and efficacy of in vivo CAR T-cell therapies in clinical trials. Risks
Evaluate the potential for immune responses and side effects from therapy. Patient & Prescribing Data
Patients with autoimmune diseases who may benefit from B-cell targeting.
In vivo CAR T-cell therapy may provide a more accessible treatment option.
Clinical Best Practices
Utilize modified LNP for targeted delivery of CAR T-cell therapies. Monitor patient responses closely during therapy. Engage in clinical trials to evaluate new CAR T-cell therapies. Related Resources & Content
